



Dansk Gynækologisk Cancer

**Danish Gynecologic Cancer
Cooperative Group**

**Mansoor Raza Mirza
The Finsen Centre
Department of Oncology
Rigshospitalet, Copenhagen**

mansoor@rh.regionh.dk



Ovarian cancer trials



Ovarian Cancer Clinical Trials Summery

First Line:

- **ICON-7**
 - GCIIG phase III
 - recruiting
- **Intraperitoneal Chemotherapy**
 - Single centre phase I-II
 - (closed)



Ovarian Cancer Clinical Trials Summery

Relapse:

Platin-Taxane sensitive


- **TC+Vorinostat**
 - multicentre phase II
 - recruiting

Platin-Taxane resistance

- TC+Belinostat – phase I (closed)

- **Carboplatin+Bevacicumab**

- singlecentre phase II
- recruiting



Vorinostat + TC


Vorinostat: a histone deacetylase (HDAC) enzymes inhibitor
Cell growth arrest, induce apoptosis, promote differentiation, inhibit
Angiogenesis, sensitize cancer cells to overcome drug resistance

Phase II


Platin & Taxane sensitive patients


Regimen
IV Carbo AUC 5 + IV Paclitaxel 175mg/m²
+ Vorinostat 400mg PO dag 1-14
Q 3 wkly
6 courses

Study status: On-going






Pelvic Mass,
A Danish clinical ovarian cancer study
Objectives

To identify potential biomarkers  for ovarian cancer(OC)

To identify prognostic factors  for ovarian cancer(OC)

What can biomarkers/prognostic factors be used for?

Prevent OC	Early diagnostic	Subgroup
		
Less women will have OC	Improved survival	Individual treatment

